Logo image of HRMY

HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis

NASDAQ:HRMY - Nasdaq - US4131971040 - Common Stock - Currency: USD

37.22  +0.53 (+1.44%)

After market: 37.22 0 (0%)

Fundamental Rating

8

Taking everything into account, HRMY scores 8 out of 10 in our fundamental rating. HRMY was compared to 194 industry peers in the Pharmaceuticals industry. HRMY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! This makes HRMY very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HRMY was profitable.
In the past year HRMY had a positive cash flow from operations.
HRMY had positive earnings in 4 of the past 5 years.
HRMY had a positive operating cash flow in 4 of the past 5 years.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of HRMY (14.49%) is better than 96.39% of its industry peers.
Looking at the Return On Equity, with a value of 21.22%, HRMY belongs to the top of the industry, outperforming 93.30% of the companies in the same industry.
With an excellent Return On Invested Capital value of 18.05%, HRMY belongs to the best of the industry, outperforming 94.33% of the companies in the same industry.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.26%. This is above the industry average of 14.87%.
Industry RankSector Rank
ROA 14.49%
ROE 21.22%
ROIC 18.05%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.56%
ROE(5y)9.52%
ROIC(3y)18.26%
ROIC(5y)15.28%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

Looking at the Profit Margin, with a value of 20.54%, HRMY belongs to the top of the industry, outperforming 93.81% of the companies in the same industry.
HRMY's Profit Margin has improved in the last couple of years.
HRMY has a better Operating Margin (28.46%) than 94.33% of its industry peers.
In the last couple of years the Operating Margin of HRMY has declined.
The Gross Margin of HRMY (78.34%) is better than 86.60% of its industry peers.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
Industry RankSector Rank
OM 28.46%
PM (TTM) 20.54%
GM 78.34%
OM growth 3Y-2.3%
OM growth 5YN/A
PM growth 3Y21.43%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

9

2. Health

2.1 Basic Checks

HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for HRMY remains at a similar level compared to 1 year ago.
The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
Compared to 1 year ago, HRMY has an improved debt to assets ratio.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 5.74 indicates that HRMY is not in any danger for bankruptcy at the moment.
HRMY has a Altman-Z score of 5.74. This is amongst the best in the industry. HRMY outperforms 80.93% of its industry peers.
The Debt to FCF ratio of HRMY is 0.79, which is an excellent value as it means it would take HRMY, only 0.79 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HRMY (0.79) is better than 96.39% of its industry peers.
HRMY has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
HRMY has a Debt to Equity ratio (0.22) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 0.79
Altman-Z 5.74
ROIC/WACC1.78
WACC10.13%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

HRMY has a Current Ratio of 3.67. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.67, HRMY is in the better half of the industry, outperforming 60.31% of the companies in the same industry.
A Quick Ratio of 3.64 indicates that HRMY has no problem at all paying its short term obligations.
HRMY has a better Quick ratio (3.64) than 62.89% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.64
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.82% over the past year.
HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
The Revenue has grown by 20.62% in the past year. This is a very strong growth!
The Revenue has been growing by 160.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7.82%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%16.42%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%19.48%

3.2 Future

HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.76% yearly.
The Revenue is expected to grow by 18.23% on average over the next years. This is quite good.
EPS Next Y34.21%
EPS Next 2Y31.45%
EPS Next 3Y28.12%
EPS Next 5Y35.76%
Revenue Next Year18.07%
Revenue Next 2Y17.87%
Revenue Next 3Y17.11%
Revenue Next 5Y18.23%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.21, which indicates a correct valuation of HRMY.
HRMY's Price/Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 87.63% of the companies in the same industry.
HRMY's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.53.
Based on the Price/Forward Earnings ratio of 8.58, the valuation of HRMY can be described as reasonable.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaper than 86.08% of the companies in the same industry.
HRMY is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.71, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.21
Fwd PE 8.58
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

HRMY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HRMY is cheaper than 90.72% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HRMY is valued cheaply inside the industry as 92.27% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.64
EV/EBITDA 7.45
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HRMY may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 28.12% in the coming years.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y31.45%
EPS Next 3Y28.12%

More info and screens

0

5. Dividend

5.1 Amount

HRMY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (7/23/2025, 4:31:02 PM)

After market: 37.22 0 (0%)

37.22

+0.53 (+1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners80.19%
Inst Owner Change0.32%
Ins Owners0.56%
Ins Owner Change0.05%
Market Cap2.14B
Analysts80
Price Target50.69 (36.19%)
Short Float %10.05%
Short Ratio6.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.9%
Min EPS beat(2)12.8%
Max EPS beat(2)31%
EPS beat(4)4
Avg EPS beat(4)117.47%
Min EPS beat(4)12.8%
Max EPS beat(4)409.61%
EPS beat(8)6
Avg EPS beat(8)58.83%
EPS beat(12)9
Avg EPS beat(12)123.33%
EPS beat(16)12
Avg EPS beat(16)89.38%
Revenue beat(2)0
Avg Revenue beat(2)-1.4%
Min Revenue beat(2)-1.83%
Max Revenue beat(2)-0.98%
Revenue beat(4)0
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-1.83%
Max Revenue beat(4)-0.91%
Revenue beat(8)1
Avg Revenue beat(8)-1.39%
Revenue beat(12)4
Avg Revenue beat(12)-0.54%
Revenue beat(16)5
Avg Revenue beat(16)-0.52%
PT rev (1m)-2.55%
PT rev (3m)-4.22%
EPS NQ rev (1m)1.5%
EPS NQ rev (3m)-6.25%
EPS NY rev (1m)0.3%
EPS NY rev (3m)7.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.6%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE 14.21
Fwd PE 8.58
P/S 2.87
P/FCF 9.64
P/OCF 9.58
P/B 2.96
P/tB 3.48
EV/EBITDA 7.45
EPS(TTM)2.62
EY7.04%
EPS(NY)4.34
Fwd EY11.65%
FCF(TTM)3.86
FCFY10.37%
OCF(TTM)3.88
OCFY10.43%
SpS12.97
BVpS12.56
TBVpS10.69
PEG (NY)0.42
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 14.49%
ROE 21.22%
ROCE 24.06%
ROIC 18.05%
ROICexc 42.52%
ROICexgc 59.55%
OM 28.46%
PM (TTM) 20.54%
GM 78.34%
FCFM 29.77%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.56%
ROE(5y)9.52%
ROIC(3y)18.26%
ROIC(5y)15.28%
ROICexc(3y)40.77%
ROICexc(5y)37.46%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexcg growth 3Y-76.77%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.85%
ROICexc growth 5YN/A
OM growth 3Y-2.3%
OM growth 5YN/A
PM growth 3Y21.43%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 0.79
Debt/EBITDA 0.67
Cap/Depr 5.3%
Cap/Sales 0.17%
Interest Coverage 12.76
Cash Conversion 94.51%
Profit Quality 144.92%
Current Ratio 3.67
Quick Ratio 3.64
Altman-Z 5.74
F-Score5
WACC10.13%
ROIC/WACC1.78
Cap/Depr(3y)59.28%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.98%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.82%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%16.42%
EPS Next Y34.21%
EPS Next 2Y31.45%
EPS Next 3Y28.12%
EPS Next 5Y35.76%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%19.48%
Revenue Next Year18.07%
Revenue Next 2Y17.87%
Revenue Next 3Y17.11%
Revenue Next 5Y18.23%
EBIT growth 1Y4.13%
EBIT growth 3Y29.72%
EBIT growth 5YN/A
EBIT Next Year52.59%
EBIT Next 3Y31.55%
EBIT Next 5Y25.65%
FCF growth 1Y40.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.96%
OCF growth 3Y30.67%
OCF growth 5YN/A